HC Wainwright Trims Pacira BioSciences (NASDAQ:PCRX) Target Price to $57.00

Pacira BioSciences (NASDAQ:PCRX) had its price objective trimmed by HC Wainwright from $63.00 to $57.00 in a research report released on Monday morning, Benzinga reports. The firm currently has a buy rating on the stock.

Other equities analysts have also issued research reports about the stock. Piper Sandler cut their price objective on shares of Pacira BioSciences from $50.00 to $42.00 and set an overweight rating for the company in a research report on Friday. Truist Financial reduced their price target on Pacira BioSciences from $60.00 to $55.00 and set a buy rating on the stock in a research note on Thursday, August 3rd. TD Cowen upgraded Pacira BioSciences from a market perform rating to an outperform rating and set a $50.00 price objective on the stock in a report on Thursday, August 3rd. StockNews.com started coverage on Pacira BioSciences in a research note on Thursday, October 5th. They issued a buy rating for the company. Finally, Needham & Company LLC lowered their price target on Pacira BioSciences from $52.00 to $45.00 and set a buy rating for the company in a report on Friday. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of Moderate Buy and a consensus price target of $52.36.

Pacira BioSciences Trading Down 1.0 %

Pacira BioSciences stock opened at $30.74 on Monday. The stock has a 50-day moving average price of $31.35 and a 200 day moving average price of $36.57. Pacira BioSciences has a 52 week low of $26.59 and a 52 week high of $53.32. The stock has a market cap of $1.43 billion, a PE ratio of 341.56 and a beta of 0.76. The company has a current ratio of 4.78, a quick ratio of 3.10 and a debt-to-equity ratio of 0.62.

Institutional Trading of Pacira BioSciences

Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in Pacira BioSciences by 1.1% in the third quarter. Vanguard Group Inc. now owns 4,868,445 shares of the company’s stock valued at $258,953,000 after buying an additional 55,188 shares during the period. Baillie Gifford & Co. raised its stake in shares of Pacira BioSciences by 1.3% in the 1st quarter. Baillie Gifford & Co. now owns 1,890,841 shares of the company’s stock valued at $77,165,000 after acquiring an additional 24,100 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Pacira BioSciences by 0.6% during the 1st quarter. Renaissance Technologies LLC now owns 1,860,997 shares of the company’s stock valued at $142,031,000 after acquiring an additional 11,800 shares in the last quarter. Frontier Capital Management Co. LLC boosted its position in Pacira BioSciences by 5.1% during the 2nd quarter. Frontier Capital Management Co. LLC now owns 1,685,255 shares of the company’s stock worth $67,528,000 after purchasing an additional 81,171 shares during the period. Finally, Stephens Investment Management Group LLC increased its holdings in Pacira BioSciences by 14.1% in the 2nd quarter. Stephens Investment Management Group LLC now owns 1,337,032 shares of the company’s stock valued at $53,575,000 after purchasing an additional 164,974 shares in the last quarter. Hedge funds and other institutional investors own 99.73% of the company’s stock.

About Pacira BioSciences

Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves.